Advances in metabolic remodeling of glutamine in pancreatic cancer

Abstract

Pancreatic cancer relies on glutamine (Gln) in its carcinogenesis. Gln metabolism is reprogrammed by multiple oncogenes and their downstream effectors in pancreatic cancer cells. The Gln dependence and its underlying molecular mechanisms can potentially be exploited as therapeutic targets. Recent research on the metabolic remodeling of Gln in pancreatic cancer has primarily focused on the inhibition of key enzymes, the impact on chemotherapy resistance, and the application of Gln antagonists. The progress in understanding Gln metabolism in pancreatic cancer offers valuable insights into potential novel therapeutic strategies.

Keywords

• glutamine|glutaminolysis|pancreatic cancer|cancer metabolism|combination therapy